How are problems with the brain diagnosed? To determine a problem with the brain, doctors may ask a patient how they feel or ...

AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...

News and commentary from the psychiatry world ...

Schizoaffective disorder is a chronic mental health condition characterized by symptoms of both schizophrenia and mood ...

A device that delivers direct stimulation to the brain is a safe and effective means of treating depression at home. New ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain ...

This technology approach marks a significant step forward in mental health care, with the potential to make impactful changes in how these conditions are managed.

Palliative care — which can include changes to medication — can alleviate symptoms and improve the quality of life for people ...

Alzamend Neuro, Inc. ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the ...

The other five goals constitute a category of “knowledge, skills, and values consistent with a liberal arts education that are further developed in psychology”: This immersive Picture Story features ...